** Sarepta Therapeutics SRPT.O said on Tuesday that a 16-year-old boy died from acute liver failure months after receiving the company's U.S.-approved gene therapy for Duchenne muscular dystrophy.
DOCTORS COULD BECOME MORE CAUTIOUS
** Jefferies ("buy"; PT: $165) says the therapy Elevidys could perhaps receive a blackbox warning for fatal acute liver-failure as a precautionary measure
** Brokerage adds if the death becomes attributed to SRPT's therapy, adoption could become more skewed towards patients who can walk and a strong trend of use by patients who cannot would reassure the Street about safety fears
** H.C. Wainwright ("sell"; PT: $75) says since the liver failure and death occurred in an older patient who could not walk, doctors could become even more cautious on dosing these patients
** William Blair ("outperform") says the recent infection in patient could have exacerbated the condition, suggesting additional safety screening measures could be implemented in the future to prevent future deaths
** BMO Capital Markets ("outperform"; PT: $200) says while this unfortunately negatively impacts Elevidys' overall safety profile, the benefit/risk profile is acceptable given unmet need in the DMD space
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.